Clinical Guides
Antiplatelet Treatment
A clinically focused, India-adapted guide to choosing single or dual antiplatelet therapy for acute coronary syndrome, ischaemic stroke, transient ischaemic attack and peripheral arterial disease while limiting avoidable bleeding.
MedNext Academy | 13 min read
Antiplatelet Treatment
A clinically focused, India-adapted guide to choosing single or dual antiplatelet therapy for acute coronary syndrome, ischaemic stroke, transient ischaemic attack and peripheral arterial disease while limiting avoidable bleeding.
Summary
Antiplatelet medicines reduce platelet activation and arterial atherothrombosis; they are not generic blood thinners for every cardiovascular risk. The prescription begins by naming the vascular indication and its time point. Acute coronary syndrome (ACS), recent coronary stenting, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack (TIA), established peripheral arterial disease (PAD), and long-term secondary prevention have different drug combinations and durations. Aspirin inhibits thromboxane production. Clopidogrel, prasugrel and ticagrelor inhibit the platelet P2Y12 pathway, with clinically important differences in onset, potency, contraindications, interactions and bleeding. Single antiplatelet therapy is the usual long-term state for stable atherosclerotic disease. Dual antiplatelet therapy (DAPT) is most valuable during defined high-risk intervals, commonly after ACS or PCI and briefly in selected minor stroke or high-risk TIA; indefinite DAPT is not the default. For ACS, a 12-month course is a standard reference, but shorter, longer or modified therapy may be appropriate after evaluating ischaemic and bleeding risks. For stroke, long-term DAPT is usually harmful, while short-course treatment is confined to qualifying patients after haemorrhage and cardioembolism are excluded. Symptomatic PAD generally warrants single antiplatelet therapy; antithrombotic intensification after revascularisation belongs to a vascular pathway. Every prescription needs a stop or review date, bleeding and gastroprotection assessment, medicine reconciliation and adherence counselling. Combining antiplatelets with anticoagulation sharply raises bleeding risk and requires a separate documented indication.
How Common Is It?
Atherosclerotic coronary, cerebral and peripheral arterial disease is common in India, where diabetes, hypertension, tobacco exposure and younger-onset cardiovascular disease create a large population potentially eligible for secondary prevention. Yet the number taking aspirin or a P2Y12 inhibitor is not the same as the number with a valid current indication. Antiplatelets are frequently begun during an emergency, after PCI, after stroke, or on a retail pharmacy's advice and may continue long after their intended combination phase. Conversely, cost, fragmented discharge information and access barriers lead some patients to stop a P2Y12 inhibitor early after coronary stenting, when thrombosis risk can be catastrophic. The expected absolute benefit varies. A patient in the early weeks after ACS has higher recurrent ischaemic risk than a stable patient years after an event; a minor non-cardioembolic stroke or high-risk TIA has a front-loaded recurrence risk; symptomatic PAD marks systemic atherosclerosis. Primary prevention is different: in people without established cardiovascular disease, aspirin's modest prevention benefit may be offset by major bleeding, so routine use is not recommended. Reliable national event and adherence estimates are incomplete, and trial populations do not capture every Indian patient with anaemia, advanced kidney disease, low body weight or delayed presentation. Clinicians should therefore avoid population slogans. Count the patient's actual vascular events, procedures, elapsed time, competing bleeding risks and whether another condition, such as atrial fibrillation, requires anticoagulation instead.
Risk Factors
Estimate both recurrent arterial-event risk and bleeding risk before deciding intensity or duration. Ischaemic risk rises with recent ACS, complex or recurrent PCI, prior stent thrombosis, multivessel disease, diabetes, chronic kidney disease, PAD, multiple vascular territories, continuing tobacco exposure and recurrent events despite adherence. Stroke recurrence depends on mechanism: large-artery atherosclerosis and selected symptomatic intracranial disease differ from atrial fibrillation, small-vessel disease or a stroke of uncertain source. PAD risk increases with diabetes, smoking, kidney disease, polyvascular disease and previous limb revascularisation. Bleeding risk increases with previous intracranial or gastrointestinal haemorrhage, active ulceration, anaemia, thrombocytopenia, older age, frailty, uncontrolled hypertension, renal or hepatic dysfunction, low body weight, heavy alcohol intake and concurrent anticoagulants, NSAIDs, corticosteroids or other haemostasis-impairing medicines. A prior ischaemic event does not erase bleeding risk, and a bleeding score cannot replace clinical review. Drug-specific factors matter: prasugrel is contraindicated after previous stroke or TIA and needs caution in older or low-weight patients; ticagrelor can cause dyspnoea and has important CYP3A interactions; clopidogrel requires metabolic activation and can be weakened by strong CYP2C19 inhibition. Gastrointestinal risk should trigger assessment for gastroprotection rather than casual discontinuation of essential therapy. Pregnancy is not itself an antiplatelet indication, and therapy used for obstetric prevention follows obstetric protocols. Finally, inability to obtain the same medicine, unclear tablet identity and an absent DAPT stop date are practical risk factors for both thrombosis and bleeding.
Diagnosis
History
Identify the index event, date, vascular territory and procedure. Ask whether the diagnosis was STEMI, NSTEMI, unstable angina, ischaemic stroke, TIA or PAD; record stent or bypass details and any cardiology or stroke plan. Establish the current antiplatelet agents, last doses, intended duration, missed doses and use of anticoagulants, NSAIDs, over-the-counter aspirin, PPIs and complementary medicines. Ask about dyspepsia, ulcer disease, melaena, haematemesis, haematuria, epistaxis, bruising, heavy menstruation, falls, dyspnoea and previous intracranial bleeding.
Examination
In an acute presentation, assess airway, haemodynamics, perfusion, oxygenation, neurological deficit and signs of ongoing bleeding. Look for pallor, petechiae, bruising, gastrointestinal tenderness, limb ischaemia, pulse deficits and heart failure. A normal external examination does not exclude intracranial, retroperitoneal or gastrointestinal haemorrhage.
Investigations
Confirm the vascular syndrome: serial ECG and cardiac troponin for ACS; urgent brain imaging for stroke to exclude haemorrhage; vascular imaging where carotid, intracranial or limb disease will alter care. Obtain full blood count, platelet count, renal and liver profiles and coagulation tests when bleeding or combination therapy is possible. Routine platelet-function testing is not required for most patients. Search for anaemia or occult blood loss before merely renewing DAPT. If an event occurs while treated, verify adherence, timing, mechanism and interactions before diagnosing resistance. In suspected TIA, immediate specialist assessment is required even if symptoms have resolved.
Differential Diagnosis
The central distinction is platelet-driven arterial thrombosis versus fibrin-rich cardioembolism or venous thrombosis. Atrial fibrillation with embolic stroke generally requires anticoagulation, not substitution with aspirin or routine DAPT. Venous thromboembolism is treated with anticoagulants. Chest pain may reflect aortic dissection, pulmonary embolism, pericarditis, myocarditis, pneumonia, pneumothorax or gastrointestinal disease; giving antiplatelets before considering dissection or active bleeding can be disastrous. Stroke-like symptoms may be intracerebral haemorrhage, hypoglycaemia, seizure with Todd paresis, migraine, tumour or functional symptoms. Brain imaging and mechanism-focused assessment determine whether acute aspirin or later antiplatelets are appropriate. Painful legs may reflect neuropathy, arthritis or venous disease rather than PAD, while acute limb ischaemia can be embolic and require a different antithrombotic strategy. Bruising during treatment may be expected minor bleeding, but falling platelets should prompt consideration of infection, immune thrombocytopenia, marrow disease, thrombotic thrombocytopenic purpura or another drug reaction. Dyspepsia is not synonymous with gastrointestinal bleeding, and a positive occult-blood test needs source evaluation. Recurrent coronary or cerebral events are not automatically treatment failure: non-adherence, early cessation, incorrect tablet, drug interaction, disease progression or a different mechanism may explain them. Primary prevention should not be confused with secondary prevention. Diabetes or a high risk score alone does not create the same benefit-to-harm balance as a documented MI, ischaemic stroke or symptomatic PAD.
Management
In suspected ACS, follow an emergency pathway with ECG, troponin, reperfusion or invasive planning and antithrombotic therapy coordinated by the receiving team. Aspirin is the foundation unless genuinely contraindicated. Add a P2Y12 inhibitor according to ACS type, planned PCI, age, bleeding risk, anticoagulation and local availability. Prasugrel is used only after anatomy is defined and PCI is intended under current guidelines guidance; prior stroke or TIA excludes it. Continue DAPT for up to 12 months after MI as a standard strategy, but individualise shorter or extended treatment. After the planned DAPT phase, long-term single therapy is usual; never let both agents continue by inertia. For suspected TIA, give immediate aspirin if not contraindicated and arrange specialist assessment within 24 hours. For confirmed non-cardioembolic minor stroke or high-risk TIA, selected early presenters may receive aspirin plus clopidogrel for a short, explicitly dated course, followed by single therapy; long-term DAPT is not recommended. Ischaemic stroke associated with AF moves to an anticoagulation pathway when safe. For symptomatic PAD, use single antiplatelet therapy with aspirin or clopidogrel alongside smoking cessation, statin therapy, blood pressure and diabetes care, exercise therapy and limb surveillance. After peripheral revascularisation, follow the vascular team's regimen; low-dose rivaroxaban plus aspirin is a distinct dual-pathway strategy, not DAPT and not full-dose anticoagulation. Review gastroprotection, correct anaemia and remove NSAIDs. If oral anticoagulation is separately needed after ACS or PCI, minimise triple therapy and document the transition plan with cardiology.
Prescribing Information
Aspirin for cardiovascular treatment is generally prescribed at a low maintenance dose after any indicated acute loading dose. Clopidogrel maintenance is commonly 75 mg once daily; ACS or PCI protocols may use a loading dose. Ticagrelor is twice daily after loading, making missed-dose counselling important. Prasugrel is once daily after loading but is contraindicated after stroke or TIA and requires caution with older age and low weight. Exact loading, maintenance and duration must follow the current indication, product label and specialist plan rather than a universal table. No routine renal dose adjustment makes a drug risk-free: chronic kidney disease increases both ischaemia and bleeding. Severe hepatic disease, active pathological bleeding and significant thrombocytopenia require specialist assessment. Pregnancy and breastfeeding decisions need obstetric and neonatal consideration; do not extrapolate low-dose aspirin used for pre-eclampsia prevention to coronary DAPT, and recognise the limited pregnancy evidence for P2Y12 inhibitors. Avoid duplicate aspirin-containing products and unnecessary NSAIDs or anticoagulants. Ticagrelor has CYP3A interactions; clopidogrel activation is inhibited by omeprazole and esomeprazole, so if a PPI is indicated choose an alternative supported by local guidance. Gastroprotection is appropriate when GI risk is high, but it does not prevent intracranial or all gastrointestinal bleeding. Antiplatelet effects cannot be monitored with INR. There is no simple universal antidote. Major bleeding management centres on stopping further doses when appropriate, resuscitation, source control, blood products and specialist advice; platelet transfusion is not automatic and may be ineffective or harmful in some contexts. Restart decisions must weigh the reason, recency of stenting and haemostasis.
When to Refer
Activate emergency care for ongoing ACS, acute stroke, TIA within the urgent window, acute limb ischaemia, haemodynamic compromise or suspected major bleeding. Cardiology review is required for DAPT selection after ACS or PCI, early interruption, recurrent ischaemia, stent thrombosis, combined anticoagulation, complex PCI and uncertainty about treatment beyond the standard course. Stroke review is required to classify mechanism, decide whether short-term DAPT criteria are met, assess carotid or intracranial disease and establish long-term single therapy. Vascular referral is needed for lifestyle-limiting claudication despite treatment, tissue loss, rest pain, threatened limb or post-revascularisation antithrombotic planning. Gastroenterology or emergency endoscopy is indicated for significant upper or lower GI bleeding; do not independently stop a P2Y12 inhibitor soon after stenting without cardiology discussion unless immediate life-saving control requires it. Haematology input is appropriate for severe thrombocytopenia, unexplained bleeding, suspected thrombotic microangiopathy or difficult perioperative haemostasis. Obstetric and cardiology teams should jointly manage pregnant patients with a coronary indication. For elective surgery, the proceduralist and antiplatelet prescriber must agree whether aspirin continues, when a P2Y12 inhibitor pauses and when it restarts. Decisions depend on bleeding risk, time since ACS or stent, and the consequence of thrombosis. Refer also when the patient cannot identify their tablets, cannot afford the prescribed agent or has no discharge record; medication access is a clinical safety problem, not merely administrative inconvenience.
Red Flags
New chest pain, dynamic ECG change, shock, pulmonary oedema or malignant arrhythmia may indicate recurrent ACS or stent thrombosis and needs emergency assessment. Sudden face, arm or speech deficit, visual loss, severe ataxia or thunderclap headache requires a stroke pathway and brain imaging; antiplatelets must not be reflexively added before haemorrhage is considered. Limb rest pain with pallor, coolness, pulselessness, paraesthesia or weakness signals threatened limb. Bleeding red flags include haematemesis, melaena, persistent haematochezia, haemodynamic instability, syncope, rapidly falling haemoglobin, intracranial symptoms, retroperitoneal pain and uncontrolled postoperative bleeding. A recent coronary stent makes interruption high stakes, so emergency, cardiology and procedural teams need immediate communication. Severe thrombocytopenia, haemolysis, neurological change, renal injury or fever after antiplatelet exposure raises a rare thrombotic microangiopathy rather than simple dose-related bruising. Breathlessness after ticagrelor is often a recognised adverse effect but must not be assumed benign until heart failure, recurrent ischaemia, pulmonary embolism, anaemia and lung disease are considered. Never respond to minor bruising by stopping DAPT without reviewing indication and time from PCI. Conversely, a prescription containing aspirin, a P2Y12 inhibitor and full-dose anticoagulation without a current documented rationale and stop date is an urgent medication-safety red flag. Before neuraxial or high-bleeding-risk surgery, unknown last P2Y12 dose or unknown stent date should delay elective action until clarified.
Indian Clinical Context
Aspirin and clopidogrel are included in India's NLEM 2022 and are widely available, but availability of ticagrelor, prasugrel, specific stent records, platelet services and specialist follow-up varies. Generic affordability can improve access, yet brand switching, fixed-dose combinations and unclear discharge prescriptions can obscure which components a patient receives. Write both generic names, the reason, once- or twice-daily frequency, and a calendar date for review or cessation of the second agent. Ask the patient to carry the PCI report or a photograph that records vessel, stent and procedure date. Early clopidogrel or ticagrelor discontinuation because the next supply was unaffordable is predictable; address it before discharge with formulary-compatible cardiology advice rather than discovering it after thrombosis. In stroke care, delayed presentation and limited imaging must not justify indiscriminate DAPT. Exclude haemorrhage, identify AF and arrange mechanism-focused follow-up. For PAD, medicine alone is inadequate: integrate tobacco cessation, foot care, exercise, diabetes care and referral for limb-threatening signs. Anaemia, peptic ulcer disease, H. pylori exposure and unsupervised NSAID use increase bleeding burden. Consider PPI gastroprotection when indicated, but avoid routine omeprazole or esomeprazole with clopidogrel when alternatives are suitable. Reconcile traditional medicines and retail-pharmacy purchases without judgement. Twice-daily ticagrelor may be less feasible for some work patterns than once-daily alternatives, but efficacy and safety determine any switch. Indian outcome evidence for some modern de-escalation or genotype-guided strategies remains limited; specialist decisions should not be portrayed as universally validated local protocols.
NMC Competency Mapping
Antiplatelet therapy links cardiovascular, neurological, peripheral vascular, pharmacological, pathological and emergency competencies. The learner should recognise ACS and stroke syndromes, perform a focused vascular and bleeding history, assess haemodynamic and neurological status, and select ECG, biomarkers, brain imaging and laboratory tests. Mechanism is central: explain platelet adhesion, activation and aggregation; distinguish cyclo-oxygenase inhibition from P2Y12 blockade; and contrast arterial antiplatelet indications with cardioembolic or venous anticoagulation. Rational-prescribing performance includes selecting single versus dual therapy, stating a start and stop or review date, checking previous stroke before prasugrel, screening for anaemia and GI risk, identifying clopidogrel-CYP2C19 interactions and counselling about adherence. Clinical reasoning includes individualising DAPT after ACS, recognising the short-term and mechanism-limited role of DAPT after minor stroke or high-risk TIA, and using single therapy in symptomatic PAD. Emergency competence includes stabilising major bleeding, arranging urgent imaging or endoscopy and seeking early input when a recent stent makes interruption dangerous. Communication competence includes explaining why two agents are temporarily necessary, why more treatment is not always better, and why over-the-counter aspirin or NSAIDs can be harmful. Suitable assessments include an ACS discharge-prescription OSCE, a post-TIA mechanism case, a GI-bleed prioritisation viva, a perioperative stent scenario and a PAD secondary-prevention station. Graduates should know evidence limits and seek current cardiology, stroke or vascular protocols for drug and duration decisions that exceed supervised practice.
Key Exam Pearls for NEET PG
Aspirin irreversibly acetylates platelet cyclo-oxygenase-1 and suppresses thromboxane A2 for the platelet lifespan. Clopidogrel and prasugrel irreversibly inhibit P2Y12; ticagrelor is a reversible P2Y12 inhibitor. DAPT means aspirin plus a P2Y12 inhibitor, not aspirin plus an anticoagulant. After ACS or MI, aspirin is generally continued long term and DAPT commonly continues for up to 12 months unless bleeding or ischaemic risk justifies modification. Prasugrel is contraindicated with prior stroke or TIA and is selected after coronary anatomy is defined when PCI is intended. Ticagrelor can cause dyspnoea and is affected by CYP3A modulators. Clopidogrel requires CYP2C19 activation; avoid routine co-prescribing of omeprazole or esomeprazole when another gastroprotective option is appropriate. Suspected TIA receives immediate aspirin if not contraindicated and specialist assessment within 24 hours. Short-term aspirin-clopidogrel is for selected early minor non-cardioembolic stroke or high-risk TIA, then single therapy; long-term DAPT is not recommended for routine stroke prevention. AF-associated stroke requires anticoagulation rather than chronic DAPT. Symptomatic PAD warrants single antiplatelet therapy, while aspirin plus vascular-dose rivaroxaban is a separate dual-pathway regimen for selected patients, not DAPT. Primary-prevention aspirin is not routinely offered because bleeding may offset benefit. Antiplatelet effect is not measured by INR and no universal reversal agent exists. In major bleeding, prioritise resuscitation, source control and specialist decisions about interruption and restart, especially when a coronary stent is recent.
Frequently Asked Questions
How long should dual antiplatelet therapy continue after ACS?
A 12-month course is a common default after MI or ACS, but it is not an automatic duration for every patient. PCI details, recurrent ischaemic risk, anaemia, previous bleeding, kidney disease, need for anticoagulation and patient preference can support shortening, extending or changing therapy. The discharge prescription should state a review date and responsible team.
Should aspirin and clopidogrel continue indefinitely after stroke?
Usually not. Short-term DAPT is reserved for selected patients with early minor non-cardioembolic stroke or high-risk TIA after haemorrhage and cardioembolism are addressed. Long-term combination therapy increases bleeding without routine added benefit. Ongoing prevention generally uses one antiplatelet, while atrial-fibrillation-related stroke usually requires an anticoagulant pathway.
Does every patient taking clopidogrel need a PPI?
No. Gastroprotection is most useful when gastrointestinal bleeding risk is elevated, such as prior ulcer or bleed, older age or concurrent ulcerogenic medicines. When a PPI is indicated with clopidogrel, avoid omeprazole and esomeprazole where suitable alternatives exist because CYP2C19 inhibition can reduce clopidogrel activation. Review the continuing need for both medicines.
Can antiplatelet medicines be stopped before surgery?
Only after the procedural and prescribing teams assess bleeding risk, indication, stent type and date, time since ACS and consequences of thrombosis. Aspirin may continue for many procedures, while a P2Y12 inhibitor may need a drug-specific pause. Early unsupervised cessation after coronary stenting can be catastrophic, and a clear restart time is part of the plan.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic